SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Bristol-Myers Squibb Co.

A Leerink downgrade and reduced outlook have put Bristol Myers pipeline and growth prospects in focus, with concerns around upcoming trial readouts and Cobenfy adoption. The cautious view contrasts with bullish posts highlighting positive multiple-myeloma data and Camzyos expanded pediatric indication.

Arbitrum is one of the leading Ethereum scaling solutions bringing cheap transactions to tens of thousands of users in an environment that feels very similar to Ethereum. It is an optimistic rollup and the leading L2 in terms of TVL. Some of the largest dApps live on Arbitrum include GMX, Radiant, Uniswap V3, and Gains Network.

Arbitrum

Robinhoods use of Arbitrum for its chain and tokenized-asset activity is the main catalyst traders cite for ARBs rally, alongside expectations that growing network activity could generate more revenue. Optimists see that adoption as a long-term positive, while skeptics argue ARB holders may not benefit without stronger token value capture and remain wary of token unlocks.

Coherent Corp. engages in the development, refinement, manufacturing, and marketing of engineered materials, opto-electronic components and devices, and lasers for use in the industrial, communications, electronics, and instrumentation markets. It operates through the following segments: Networking, Materials, and Lasers. The Networking segment leverages compound semiconductor technology platforms and deep knowledge of end-user applications. The Materials segment markets engineered materials and optoelectronic devices. The Lasers segment serves industrial customers in semiconductor capital equipment, display capital equipment, precision manufacturing, and aerospace and defense, as well as instrumentation customers in life sciences and scientific research. The company was founded by Carl J. Johnson in 1971 and is headquartered in Saxonburg, PA.

Coherent Corp

Coherent is drawing attention as traders focus on AI data-center demand for optical networking and the potential for suppliers such as COHR to benefit from Lumentums reported capacity shortfall; discussion also highlights Coherents PhotonLink platform. Sentiment is broadly bullish on the optics theme, but traders are divided over the stocks sharp swings, recent pullbacks and whether its gains can hold.

Aerodrome Finance is a next-generation AMM designed to serve as Base's central liquidity hub, combining a powerful liquidity incentive engine, vote-lock governance model, and friendly user experience. Aerodrome inherits the latest features from Velodrome V2.

Aerodrome Finance

AEROs sharp rally has traders focused on the planned AerodromeVelodrome merger and multichain expansion, including an Ethereum mainnet rollout, which the community expects could broaden liquidity and revenue. Bullish posts highlight the expansion and a potential break above the psychological $1 level, while others question whether the catalyst is already priced in or could prompt a sell-the-news reaction.

StarkNet is a permissionless decentralized Layer 2 (L2) validity rollup, built to allow Ethereum to scale via cryptographic protocols called STARKs, without compromising Ethereum’s core principles of decentralization, transparency, inclusivity and security. The StarkNet Token is needed to operate the ecosystem, maintain and secure it, decide on its values and strategic goals, and direct its evolution. This token will be required for (i) governance, (ii) payment of transaction fees on StarkNet, and (iii) participation in StarkNet’s consensus mechanism.

Starknet

STRKs sharp rally and breakout are driving attention, with traders linking the move to Starknets post-quantum security, privacy features and Bitcoin DeFi, as well as speculation about a possible shift toward an independent Layer 1. Momentum-driven optimism and FOMO are tempered by concerns about profit-taking, token-supply pressure and a potential pump-and-dump.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

CAN-2409s prostate-cancer trial results and additional biomarker findings are driving attention, alongside Candels stated plan to submit a BLA in Q4 2026. Traders are divided between optimism about the data and skepticism over the muted share-price response, filing timeline, cash needs, and CEO share sales.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

Merck and Modernas personalized mRNA melanoma vaccine met key Phase 3 endpoints when combined with Keytruda, lifting optimism about Mercks oncology pipeline and the potential to strengthen its franchise ahead of Keytrudas patent expiration. Traders are largely bullish on the validation, though some question how much the results justify in valuation given that full data, overall-survival results and regulatory progress remain outstanding.

What is the project about? Pepe is a community based meme token surround the iconic meme Pepe the frog. Pepe aims to leverage the power of such an iconic meme to become the most memeable memecoin in existence.   What makes your project unique? Pepe is here to make memecoins great again. Ushering in a new paradigm for memecoins, Pepe represents the memecoin in it's purest simplicity. With zero taxes, liquidity locked forever, and contract immutable, Pepe is for the people, forever. Pepe is about culture, rallying together a community to have fun and enjoy memes, fueled purely by memetic power.   History of your project. Pepe was stealth launched on Friday, April 14th, 2023.   What’s next for your project? Pepe will focus on developing a tight-knit community around the token and building resources to enrich the communities knowledge and success in crypto through a token gated group, newsletter, and more tools.   What can your token be used for? Pepe can be used to speculate on the power of memes, and does not pretend to be anything more.

Pepe

PEPE is drawing attention for choppy consolidation around the 0.000004 level after recent swings, with traders watching whether it can break above resistance near 0.000005 or slip lower. The conversation is split between holders anticipating another meme-coin rally and skeptics warning that rebounds are fading and PEPE is lagging other crypto moves.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Kodiaks positive Phase 3 data for its wet-AMD drug intensified competition concerns and weighed on Ocular Therapeutix. Bulls argue AXPAXLIs SOL-1 durability results and planned NDA filing could distinguish it, while skeptics question how well those results will translate into adoption and against rival treatments.

Vaxcyte, Inc. engages in the development of vaccines for infectious diseases. It focuses on conjugate vaccines and protein-based vaccines developed through the Sutro Biopharma's Xpress CF Platform, a cell-free protein synthesis technology. The company was founded by Grant E. Pickering and Jeff Fairman on November 27, 2013, and is headquartered in San Carlos, CA.

Vaxcyte Inc

Vaxcytes VAX-31 met the primary endpoints in its pivotal Phase 3 OPUS-1 trial, drawing attention to the candidates potential against established pneumococcal vaccines and the next clinical milestones. Traders are weighing that positive data against the companys large financing plans and potential dilution, with bullish reactions competing with profit-taking and bearish skepticism.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 
